Original Research
Accepted on 17 Nov 2025
Neoadjuvant chemoradiotherapy plus programmed cell death protein-1 blockade versus chemoradiotherapy alone for muscle-invasive bladder cancer: a real-world comparative study
in Cancer Immunity and Immunotherapy